Biochem/physiol Actions
Target IC50: 0.35 µM against HER2
Reversible: yes
Product does not compete with ATP.
Primary TargetHER2
Cell permeable: yes
General description
A potent, cell-premeable, reversible, substrate competitive, and selective inhibitor of HER-2 (neu/erbB-2, IC50 = 0.35 µM) relative to HER-1 (IC50 = 19 µM) autophosphorylation. The inhibition is competitive with respect to ATP binding. Enhances the chemosensitivity in non-small cell lung cancer (NSCLC) cell lines expressing high levels of p185neu.
A potent, cell-premeable, reversible, substrate competitive, and selective inhibitor of HER2 (neu/ErbB2; IC50 = 0.35 µM) relative to HER1 (IC50 = 19 µM) autophosphorylation. The inhibition is competitive with respect to ATP binding. Enhances chemosensitivity in non-small cell lung cancer (NSCLC) cell lines expressing high levels of p185neu.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Ashton, J.M., et al. 2012. Cell Stem Cell11, 359.Tsai, C.M., et al. 1996. Cancer Res.56, 1068.Levitzki, A., and Gazit, A. 1995. Science267, 1782.Osherov, N., et al. 1993. J. Biol. Chem. 268, 11134.
Packaging
2 mg in Plastic ampoule
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2-3 months at -20°C.
Warning
Toxicity: Standard Handling (A)
This product has met the following criteria to qualify for the following awards: